Client Success: Valuation Analysis for Revenue Cycle Healthcare Technology Spin-Out
THE PROBLEM: Determine the fair market value of a spin-out of an existing successful healthcare technology company for purposes of tax and transaction planning purposes. THE SOLUTION: Financial modeling and diligence, transaction support and fair market value opinion. “You are our go to team for valuation support. You know your domain and are responsive.” – […]
Client Success: Healthcare Transaction Support to Assess Value from Different Perspectives
By Jeff Williamson THE SITUATION: A healthcare company with a portfolio of products in development for treating cardiac conditions was fielding investor interest for a potential acquisition. The company wanted to weigh the relative merits of raising additional equity financing versus exploring multiple M&A offers, as these initial discussions indicated a price range that did […]
Client Success: Mandatory Adoption of ASC 842 – Incremental Borrowing Rate Analysis for Private Biotech
By Jeff Suchocki, CFA The Situation: Adoption of ASC 842 – Lease Accounting is mandatory for all private companies for fiscal years beginning after December 15, 2021. To comply with this mandatory adoption requirement, a privately held, clinical stage biotech company needed to understand a reasonable discount rate for multiple lease agreements. The company requested […]
Client Success: Strategic Extension for Revenue-Stage Medtech Company
By Jeff Williamson THE SITUATION: A medical device company was preparing to launch a novel product used in interventional cardiac surgeries — one that offered improved performance, simplified clinical workflows, and reduced procedure times. The company asked RNA to help it quantify the benefits of the new device in light of direct cost savings, workflow streamlining, […]
Client Success: Navigating Strategic Investment in Healthcare Technology
THE PROBLEM: A healthcare technology company that sells its FDA 510(k) approved device and supporting dashboarding and analytic tools to hospitals was in the midst of a capital raising effort involving a one-on-one negotiation with an existing strategic partner. The company received from the strategic partner a “low-ball” valuation. The company’s management team and board […]
Client Success: Incremental Borrowing Rate Analysis for Publicly Traded, Clinical Stage Biotech
THE PROBLEM: A publicly traded clinical stage biotech company needed to understand the correct implied discount rate for a lease agreement in accordance with ASC 842 rules. THE SOLUTION: ASC 842 has specific rules relating to leases, including guidance on lease classification (operating versus financial) and how to discount a lessee’s lease payments to arrive […]
Client Success: Derivatives Valuation for pre-IPO Biotechnology Company
THE PROBLEM: A development stage biotechnology company (considering an IPO in the near future) entered into a series of financings which required the valuation of components of the financings deemed to be a derivative for financial reporting purposes. THE SOLUTION: RNA worked with the company and their Big 4 auditor to develop a Monte Carlo […]
Client Success: Commercial Assessment for Crossover Investor-Funded Private Biotech
THE PROBLEM: Novel technology platform could be used across a wide range of rare diseases, so executive team and board want an independent, evidence-based view of commercial opportunity to complement the scientific analysis. THE SOLUTION: Interviews with KOL physician-scientists to understand unmet need and applicability of technology to targets, detailed pipeline analysis, market modeling and […]
Client Success: Valuation Support for Licensing Transaction – Novel Cancer Therapy
THE PROBLEM: Publicly traded late-stage therapeutics company negotiates with, and enters into, collaboration / license arrangement with a big pharma partner. THE SOLUTION: Forecasting, market research, modeling and transaction support combined with resultant collaboration agreement accounting analyses. “You were a great support for us, responsive and knowledgeable. Thank you!” CFO “You are my top go […]
Client Success: Portfolio Valuation for LPs of $1B + Healthcare-Focused PE Firm
THE PROBLEM: Two of the largest pension funds in the world required an independent valuation assessment of the portfolio of a multi-billion dollar life science/ healthcare private equity fund. THE SOLUTION: Robust research, forecasting, modeling, comp analysis and valuation analytics to determine reasonableness of value indications. “We love working with you. You actually know what […]
